{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:07:13Z","timestamp":1794017233643,"version":"4.8.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"UNM Comprehensive Cancer Center","id":[{"id":"https:\/\/ror.org\/05kx2e072","id-type":"ROR","asserted-by":"crossref"}]},{"name":"UNM Pathology Department"},{"name":"UNM HSC Research Allocation Committee Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14811-8","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:45:33Z","timestamp":1759229133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Parisa","family":"Nikeghbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa","family":"Zamanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara P.","family":"Steinkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"5","key":"14811_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Reviews Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"14811_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Canc Netw"},{"key":"14811_CR3","first-page":"45","volume":"5","author":"Z Kemp","year":"2013","unstructured":"Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health. 2013;5:45\u201351.","journal-title":"Int J Womens Health"},{"issue":"4","key":"14811_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"Cancer J Clin"},{"key":"14811_CR5","doi-asserted-by":"crossref","unstructured":"Matulonis UA et al. Ovarian cancer (Primer). Nat Reviews: Disease Primers, 2016. 2(1).","DOI":"10.1038\/nrdp.2016.61"},{"issue":"3","key":"14811_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M. Platinum resistant ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624\u201331.","journal-title":"Gynecol Oncol"},{"key":"14811_CR7","volume-title":"Principles and practice of gynecologic oncology","author":"RR Barakat","year":"2009","unstructured":"Barakat RR, Markman M, Randall M. Principles and practice of gynecologic oncology. Lippincott Williams & Wilkins; 2009."},{"issue":"8","key":"14811_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/biomedicines9081021","volume":"9","author":"JW Gorski","year":"2021","unstructured":"Gorski JW, et al. Utilizing patient-derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance. Biomedicines. 2021;9(8):1021.","journal-title":"Biomedicines"},{"issue":"5","key":"14811_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838\u201349.","journal-title":"Nat Med"},{"key":"14811_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2013.00295","volume":"3","author":"CL Scott","year":"2013","unstructured":"Scott CL, et al. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013;3:295.","journal-title":"Front Oncol"},{"issue":"29","key":"14811_CR11","doi-asserted-by":"publisher","first-page":"28327","DOI":"10.18632\/oncotarget.5069","volume":"6","author":"P-E Colombo","year":"2015","unstructured":"Colombo P-E, et al. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget. 2015;6(29):28327.","journal-title":"Oncotarget"},{"issue":"5","key":"14811_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1078-0432.CCR-16-1237","volume":"23","author":"JF Liu","year":"2017","unstructured":"Liu JF, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res. 2017;23(5):1263\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"14811_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2767-9764.CRC-22-0300","volume":"3","author":"MP Steinkamp","year":"2023","unstructured":"Steinkamp MP, et al. Humanized patient-derived xenograft models of disseminated ovarian cancer recapitulate key aspects of the tumor immune environment within the peritoneal cavity. Cancer Res Commun. 2023;3(2):309\u201324.","journal-title":"Cancer Res Commun"},{"issue":"4","key":"14811_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/MOH.0000000000000349","volume":"24","author":"M Pizzi","year":"2017","unstructured":"Pizzi M, Inghirami G. Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease? Curr Opin Hematol. 2017;24(4):384\u201392.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"14811_CR15","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1038\/s41598-017-06912-7","volume":"7","author":"M Moro","year":"2017","unstructured":"Moro M, et al. Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. Sci Rep. 2017;7(1):6689.","journal-title":"Sci Rep"},{"issue":"12","key":"14811_CR16","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","volume":"58","author":"W Senkowski","year":"2023","unstructured":"Senkowski W, et al. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev Cell. 2023;58(12):1106\u201321. e7.","journal-title":"Dev Cell"},{"issue":"4","key":"14811_CR17","first-page":"910","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, et al. 2D and 3D cell cultures\u2013a comparison of different types of cancer cell cultures. Archives Med Sci. 2018;14(4):910\u20139.","journal-title":"Archives Med Sci"},{"key":"14811_CR18","doi-asserted-by":"crossref","unstructured":"\u015awierczewska M, et al. The response and resistance to drugs in ovarian cancer cell lines in 2D monolayers and 3D spheroids. Volume 165. Biomedicine & Pharmacotherapy; 2023. p. 115152.","DOI":"10.1016\/j.biopha.2023.115152"},{"issue":"12","key":"14811_CR19","doi-asserted-by":"publisher","first-page":"e0244549","DOI":"10.1371\/journal.pone.0244549","volume":"15","author":"B Patra","year":"2020","unstructured":"Patra B, et al. Carboplatin sensitivity in epithelial ovarian cancer cell lines: the impact of model systems. PLoS ONE. 2020;15(12):e0244549.","journal-title":"PLoS ONE"},{"issue":"7","key":"14811_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00018-022-04395-y","volume":"79","author":"A Ciucci","year":"2022","unstructured":"Ciucci A, et al. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. Cell Mol Life Sci. 2022;79(7):364.","journal-title":"Cell Mol Life Sci"},{"key":"14811_CR21","doi-asserted-by":"publisher","first-page":"836984","DOI":"10.3389\/fbioe.2022.836984","volume":"10","author":"C Yee","year":"2022","unstructured":"Yee C, et al. Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine. Front Bioeng Biotechnol. 2022;10:836984.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"14811_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2019.05.005","volume":"154","author":"Y Maru","year":"2019","unstructured":"Maru Y, et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol. 2019;154(1):189\u201398.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"14811_CR23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112\u201329.","journal-title":"Cancer Discov"},{"issue":"6","key":"14811_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2018.09.016","volume":"23","author":"HH Yan","year":"2018","unstructured":"Yan HH, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23(6):882\u201397. e11.","journal-title":"Cell Stem Cell"},{"key":"14811_CR25","doi-asserted-by":"crossref","unstructured":"de Witte CJ et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter-and intrapatient drug responses. Cell Rep, 2020. 31(11).","DOI":"10.1016\/j.celrep.2020.107762"},{"issue":"513","key":"14811_CR26","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","volume":"11","author":"SN Ooft","year":"2019","unstructured":"Ooft SN, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11(513):eaay2574.","journal-title":"Sci Transl Med"},{"issue":"6378","key":"14811_CR27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, et al. Patient-derived organoids model treatment response of metastatic Gastrointestinal cancers. Science. 2018;359(6378):920\u20136.","journal-title":"Science"},{"issue":"11","key":"14811_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.15252\/msb.20177697","volume":"13","author":"J Jabs","year":"2017","unstructured":"Jabs J, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol. 2017;13(11):955.","journal-title":"Mol Syst Biol"},{"issue":"11","key":"14811_CR29","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","volume":"31","author":"CJ de Witte","year":"2020","unstructured":"de Witte CJ, et al. Patient-Derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous Inter- and intrapatient drug responses. Cell Rep. 2020;31(11):107762.","journal-title":"Cell Rep"},{"key":"14811_CR30","unstructured":"Larsen BM et al. A pan-cancer organoid platform for precision medicine. Cell Rep, 2021. 36(4)."},{"issue":"1","key":"14811_CR31","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.1038\/s41598-020-69488-9","volume":"10","author":"Y Nanki","year":"2020","unstructured":"Nanki Y, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep. 2020;10(1):12581.","journal-title":"Sci Rep"},{"issue":"3","key":"14811_CR32","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.xpro.2023.102402","volume":"4","author":"SD Scherer","year":"2023","unstructured":"Scherer SD, et al. Breast cancer PDxO cultures for drug discovery and functional precision oncology. STAR Protocols. 2023;4(3):102402.","journal-title":"STAR Protocols"},{"issue":"2","key":"14811_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen KP, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3(2):232\u201350.","journal-title":"Nat Cancer"},{"issue":"19","key":"14811_CR34","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-23-0705","volume":"83","author":"J Navarro-Yepes","year":"2023","unstructured":"Navarro-Yepes J, et al. Abemaciclib is effective in palbociclib-resistant hormone receptor\u2013positive metastatic breast cancers. Cancer Res. 2023;83(19):3264\u201383.","journal-title":"Cancer Res"},{"issue":"1","key":"14811_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-023-02809-8","volume":"42","author":"L Thorel","year":"2023","unstructured":"Thorel L, et al. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J Experimental Clin Cancer Res. 2023;42(1):260.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"12","key":"14811_CR36","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3390\/cancers13122901","volume":"13","author":"J Bi","year":"2021","unstructured":"Bi J, et al. Successful patient-derived organoid culture of gynecologic cancers for disease modeling and drug sensitivity testing. Cancers. 2021;13(12):2901.","journal-title":"Cancers"},{"key":"14811_CR37","first-page":"pe66072","volume":"203","author":"KE Colling","year":"2024","unstructured":"Colling KE, et al. Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer. JoVE (Journal Visualized Experiments). 2024;203:pe66072.","journal-title":"JoVE (Journal Visualized Experiments)"},{"issue":"13Supplement","key":"14811_CR38","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1158\/1538-7445.AM2018-1619","volume":"78","author":"HA Swan","year":"2018","unstructured":"Swan HA, et al. Personalized medicine: a CLIA-certified high-throughput drug screening platform for ovarian cancer. Cancer Res. 2018;78(13Supplement):1619\u20131619.","journal-title":"Cancer Res"},{"issue":"2","key":"14811_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.20517\/cdr.2022.01","volume":"5","author":"PG Rose","year":"2022","unstructured":"Rose PG. Ovarian cancer recurrence: is the definition of platinum sensitivity modified by parpi, bevacizumab or other intervening treatments? A clinical perspective. Cancer Drug Resist. 2022;5(2):415.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"14811_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol. 1992;10(4):513\u20134.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14811_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.23.01771","volume":"42","author":"J St Laurent","year":"2024","unstructured":"St Laurent J, Liu JF. Treatment approaches for Platinum-Resistant ovarian cancer. J Clin Oncol. 2024;42(2):127\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14811_CR42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1186\/s12885-023-11434-9","volume":"23","author":"J Gao","year":"2023","unstructured":"Gao J, et al. Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper Gastrointestinal cancers: progress and challenges. BMC Cancer. 2023;23(1):1205.","journal-title":"BMC Cancer"},{"issue":"9","key":"14811_CR43","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber F, et al. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biology. 2017;24(9):1092\u2013100.","journal-title":"Cell Chem Biology"},{"issue":"5","key":"14811_CR44","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/gb-2014-15-5-r75","volume":"15","author":"SN Porter","year":"2014","unstructured":"Porter SN, et al. Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo. Genome Biol. 2014;15(5):R75.","journal-title":"Genome Biol"},{"issue":"6","key":"14811_CR45","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41585-022-00706-x","volume":"20","author":"MG Lawrence","year":"2023","unstructured":"Lawrence MG, et al. The future of patient-derived xenografts in prostate cancer research. Nat Reviews Urol. 2023;20(6):371\u201384.","journal-title":"Nat Reviews Urol"},{"issue":"9","key":"14811_CR46","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998\u20131013.","journal-title":"Cancer Discov"},{"issue":"1","key":"14811_CR47","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1):373\u201386. e10.","journal-title":"Cell"},{"issue":"4","key":"14811_CR48","doi-asserted-by":"publisher","first-page":"e100300","DOI":"10.15252\/embj.2018100300","volume":"38","author":"N Sachs","year":"2019","unstructured":"Sachs N, et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 2019;38(4):e100300.","journal-title":"EMBO J"},{"issue":"10","key":"14811_CR49","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/nm.2470","volume":"17","author":"P Jung","year":"2011","unstructured":"Jung P, et al. Isolation and in vitro expansion of human colonic stem cells. Nat Med. 2011;17(10):1225\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"14811_CR50","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2011.07.050","volume":"141","author":"T Sato","year":"2011","unstructured":"Sato T, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and barrett\u2019s epithelium. Gastroenterology. 2011;141(5):1762\u201372.","journal-title":"Gastroenterology"},{"issue":"10","key":"14811_CR51","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/ncb3047","volume":"16","author":"CW Chua","year":"2014","unstructured":"Chua CW, et al. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol. 2014;16(10):951\u201361.","journal-title":"Nat Cell Biol"},{"issue":"24","key":"14811_CR52","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","volume":"81","author":"V Gil","year":"2021","unstructured":"Gil V, et al. HER3 is an actionable target in advanced prostate cancer. Cancer Res. 2021;81(24):6207\u201318.","journal-title":"Cancer Res"},{"issue":"2","key":"14811_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173(2):515\u201328. e17.","journal-title":"Cell"},{"issue":"1","key":"14811_CR54","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1038\/s41598-021-83662-7","volume":"11","author":"EY Cai","year":"2021","unstructured":"Cai EY, et al. A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. Sci Rep. 2021;11(1):4609.","journal-title":"Sci Rep"},{"key":"14811_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-016-0548-9","volume":"15","author":"J Gonzalez Bosquet","year":"2016","unstructured":"Gonzalez Bosquet J, et al. Prediction of chemo-response in serous ovarian cancer. Mol Cancer. 2016;15:1\u201315.","journal-title":"Mol Cancer"},{"issue":"7","key":"14811_CR56","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/ph14070682","volume":"14","author":"J Bi","year":"2021","unstructured":"Bi J, et al. Advantages of tyrosine kinase anti-angiogenic cediranib over bevacizumab: cell cycle abrogation and synergy with chemotherapy. Pharmaceuticals. 2021;14(7):682.","journal-title":"Pharmaceuticals"},{"issue":"12","key":"14811_CR57","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, et al. Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424\u201335.","journal-title":"Nat Med"},{"issue":"4","key":"14811_CR58","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M Van de Wetering","year":"2015","unstructured":"Van de Wetering M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933\u201345.","journal-title":"Cell"},{"issue":"1","key":"14811_CR59","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41698-023-00478-6","volume":"7","author":"AT Sengal","year":"2023","unstructured":"Sengal AT, et al. Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR Inhibition. Npj Precision Oncol. 2023;7(1):127.","journal-title":"Npj Precision Oncol"},{"key":"14811_CR60","doi-asserted-by":"publisher","first-page":"106232","DOI":"10.1016\/j.phrs.2022.106232","volume":"179","author":"M Tao","year":"2022","unstructured":"Tao M, et al. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer. Pharmacol Res. 2022;179:106232.","journal-title":"Pharmacol Res"},{"issue":"8","key":"14811_CR61","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.7150\/thno.96027","volume":"14","author":"D Xiang","year":"2024","unstructured":"Xiang D, et al. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics. 2024;14(8):3300.","journal-title":"Theranostics"},{"issue":"1","key":"14811_CR62","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Therapy. 2023;8(1):160.","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"14811_CR63","first-page":"263","volume":"2","author":"E Wang","year":"2022","unstructured":"Wang E, et al. Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): new opportunities in Establishing faithful pre-clinical cancer models. J Natl Cancer Cent. 2022;2(4):263\u201376.","journal-title":"J Natl Cancer Cent"},{"key":"14811_CR64","doi-asserted-by":"crossref","unstructured":"Nikeghbal P et al. The Influence of Macrophages within the Tumor Microenvironment on Ovarian Cancer Growth and Response to Therapies. bioRxiv, 2025: p. 2025.01.29.635532.","DOI":"10.1101\/2025.01.29.635532"},{"issue":"7","key":"14811_CR65","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175(7):1972\u201388. e16.","journal-title":"Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14811-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:29:31Z","timestamp":1759274971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14811"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14811-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.28.601283","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki. Malignant ascites was collected from OC patients undergoing cytoreductive surgery at the University of New Mexico (UNM) Comprehensive Cancer Center. Informed consent was obtained from all participants included in the study. Ascites collection and patient-derived xenograft (PDX) models were established under a protocol approved by the University of New Mexico Health Sciences Center Institutional Review Board (INST 1509). All animal studies, including the development of PDX models, were approved by the University of New Mexico Health Sciences Center Institutional Animal Care and Use Committee (protocol#: 21-20144-HSC and 24-20153-HSC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1459"}}